Rheumatology Portfolio Pathway: a complete guide for senior doctors.

The rheumatology route in brief

Rheumatology reaches the Specialist Register by the same two routes as every specialty: a Certificate of Completion of Training (CCT) at the end of UK training, or the Portfolio Pathway for doctors who have not completed a UK approved programme but can demonstrate equivalent knowledge, skills and experience. If you are new to the route, start with the complete guide to the Portfolio Pathway; this article assumes that grounding and focuses on what is specific to rheumatology.

Rheumatology has a different shape from the procedure-dominated specialties. Where gastroenterology lives or dies on endoscopy, rheumatology is carried by clinical breadth: the diagnosis and long-term management of inflammatory, autoimmune and metabolic bone disease, with a procedural component that matters but does not dominate. That makes the evidence more about demonstrating sound, broad, consultant-level judgement across a wide disease range than about a single logbook.

The spine of your application is the General Medical Council (GMC) Specialty Specific Guidance (SSG) for Rheumatology with General Internal Medicine, read alongside the 2022 rheumatology curriculum and the internal medicine curriculum. Read all three before gathering anything, plus the resources from the British Society for Rheumatology (BSR). We explain how to read an SSG in general in the SSG guide.

Rheumatology with General Internal Medicine

The first thing to understand is that rheumatology is a Group 1 specialty, which means it dual trains with Internal Medicine, and the internal medicine learning outcomes are embedded in the rheumatology curriculum. The SSG is framed as Rheumatology with GIM. So unlike dermatology, which is decoupled from the acute take, rheumatology normally means a dual application: you evidence the rheumatology capabilities and the internal medicine capabilities, including the acute medical take, together.

This matters for planning, because the GIM evidence is not optional padding: it is half of a dual application and assessors expect it to be real. Many rheumatology applicants are strong on the specialty and thin on the acute take, particularly if their current post is outpatient-heavy. If your experience genuinely does not include GIM, you may apply in rheumatology alone, but be realistic that most consultant posts expect a medical take contribution. We cover the dual question in the guide on dual certification.

For many senior SAS doctors and non-substantive consultants already working at a rheumatology specialty level in the UK, this is reassuring rather than daunting. If you run independent clinics, manage biologics, perform injections and contribute to the take, the consultant-shaped work is already happening; the Portfolio Pathway is largely about packaging that existing practice as evidence mapped to the curriculum. The task is less about acquiring new experience and more about capturing, validating and organising what you already do, which is exactly the framing the rest of this guide takes.

The 2022 curriculum and its capabilities

The 2022 rheumatology curriculum is built on Capabilities in Practice (CiPs): high-level descriptions of what a day-one consultant can do. Your evidence has to demonstrate each at the level of unsupervised practice. Knowing the structure helps, because it is the framework your portfolio will be mapped against.

Because the curriculum allows dual running during the transition period, you may apply under the 2022 curriculum or the previous version; check the current position in your SSG, and unless you have a strong reason otherwise, work to the 2022 one. The underlying logic of CiPs, and how to map evidence to them, sits in the Capabilities in Practice guide, within the four GMC domains.

Joint injection and musculoskeletal ultrasound

Rheumatology's procedural component is real but proportionate. The core procedural skill is joint and soft tissue injection and aspiration, and you must evidence safe, independent competence across a range of sites and indications. This is not a thousand-procedure logbook in the way endoscopy is, but it is a defined capability, and an application that cannot show validated procedural competence has a gap.

Musculoskeletal ultrasound is increasingly part of modern rheumatology, supporting both diagnosis and guided injection. It is valued and for some posts expected, but it is not a universal absolute requirement for every applicant. If you perform it, evidence your training and a validated record; if you do not, that is not automatically a barrier, but check what your SSG expects and make sure the injection competence the curriculum does require is clearly demonstrated. The detail of building an injection logbook is covered in the dedicated guide on joint injection evidence.

Biologics, DMARDs and shared-care governance

If there is a strand that genuinely defines modern rheumatology evidence, it is the governance of advanced therapies. Disease-modifying antirheumatic drugs (DMARDs) and biologic and targeted synthetic therapies have transformed outcomes in inflammatory arthritis and autoimmune disease, and with them comes a substantial governance responsibility: initiation, monitoring, shared care with primary care, registries, and the management of risk and complications.

Evidencing that you initiate and monitor these therapies safely, within local and national governance frameworks, demonstrates exactly the consultant-level judgement assessors want. It maps across several capabilities at once, from clinical management to safety and teamwork, and it is hard to assemble convincingly from a system that does not run shared-care prescribing the way the NHS does. Make it explicit in your evidence rather than leaving it implied in clinic letters.

What evidence you need

Before the inventory, one strand that sits between the specialty and the acute take and is easy to under-evidence: acute and emergency rheumatology. Giant cell arteritis with threatened vision, septic arthritis, acute systemic vasculitis and severe lupus flares are genuine emergencies that present urgently and demand rapid, confident management. They are where rheumatology meets acute medicine, and they map neatly onto both the specialty and the GIM capabilities at once. Evidence from urgent referrals, the giant cell arteritis pathway, hot joint assessment and on-call advice shows that you manage the unwell rheumatology patient, not only the stable outpatient. That is exactly the kind of evidence that distinguishes a consultant-level portfolio from a competent specialty-trainee one, and it strengthens a dual application on both sides. A single well-documented giant cell arteritis case, from urgent presentation through to treatment and follow-up, can evidence acute management, the specialty knowledge base and multidisciplinary working all at once, so it is worth capturing these cases carefully when they arise.

The procedural and governance strands sit within a complete application that maps across the whole curriculum using the same evidence types as every specialty. The table below is the working inventory.

The cross-specialty evidence types each repay being built deliberately. We cover the workhorses in depth: multi-source feedback, workplace-based assessments, audit, and structured reports and referees. To apply via the Portfolio Pathway you also need a relevant specialist qualification, such as the Specialty Certificate Examination (SCE) in Rheumatology, or at least six months of continuous specialist training gained outside a UK programme. Confirm the exact requirement in the SSG before you start.

Subspecialty breadth

Rheumatology is broad, and assessors look for evidence across its main areas rather than depth in only one. A portfolio that is all inflammatory arthritis and no connective tissue disease, or all clinic and no metabolic bone work, looks unbalanced against a curriculum built for general specialty practice. Think in three broad areas and make sure each is genuinely represented.

The multisystem nature of autoimmune disease means rheumatologists work closely with nephrology, respiratory, dermatology and others, often in combined clinics. Evidence of that multidisciplinary working is valuable, because it shows you manage complex disease the way UK consultant practice expects. If you have a defined special interest, whether that is vasculitis, connective tissue disease or metabolic bone, lean into it as evidence of depth, provided the general breadth is also there. The guide on special interest areas covers how to evidence one.

A realistic timeline

Most candidates take two to four years from starting evidence collection to Specialist Register entry. Rheumatology is less constrained by a single procedural bottleneck than endoscopy-heavy or surgery-heavy specialties, but the breadth of inflammatory, autoimmune and metabolic bone disease, plus the dual GIM evidence and the procedural competence, still takes time to assemble and date properly.

The processing time after submission is the same as for any specialty: the GMC's published guidance is six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months from submission to outcome, on top of the evidence-building years. The full sequence is in the timeline guide, and what happens after you submit in the after-submission guide.

The biggest variable, as ever, is your post. A department with general clinics across the disease range, a biologics service, injection lists, access to ultrasound training, and a GIM commitment makes a dual application achievable. An outpatient-only post with no acute take and a narrow case mix makes the GIM and breadth evidence very hard to build. That is worth weighing honestly when you plan, and sometimes worth acting on.

Why rheumatology applications stall

Related guides

Rheumatology sits within the wider library of specialism overviews and the cross-cutting evidence guides. If you are still choosing or confirming your specialty, the guide on choosing your specialty helps. The full set of specialism overviews:

Build these alongside your application

The procedural and governance evidence is specialty-specific, but the rest of the portfolio draws on the same cross-cutting evidence types as every application. Build these in parallel.

Frequently asked questions

Is rheumatology assessed together with General Internal Medicine?

Usually yes. Rheumatology is a Group 1 specialty, so it dual trains with Internal Medicine, and the GMC Specialty Specific Guidance is for Rheumatology with General Internal Medicine. The internal medicine learning outcomes are embedded in the 2022 rheumatology curriculum. So a typical application is dual, satisfying the internal medicine capabilities and the acute take evidence alongside the rheumatology requirements. Most substantive consultant posts expect a GIM contribution, so the dual application is also the more employable route.

Do I need musculoskeletal ultrasound for the rheumatology Portfolio Pathway?

Not as an absolute requirement for everyone, but it is increasingly valued and for some posts it is expected. Musculoskeletal ultrasound supports diagnosis and guided injection and is part of modern rheumatology practice. If you perform it, evidence your training and a validated record of scans. If you do not, that is not automatically a barrier, but check your Specialty Specific Guidance and be ready to show competence in the procedural skills the curriculum does require, principally joint and soft tissue injection.

Do I need the SCE in Rheumatology for the Portfolio Pathway?

You need a relevant specialist qualification, or at least six months of continuous specialist training in rheumatology gained outside a UK programme. The Specialty Certificate Examination (SCE) in Rheumatology, run through MRCP(UK), is the clearest way to evidence the specialty knowledge base, and many successful applicants hold it. If you do not, you must show equivalent specialist training and a knowledge base evidenced across the curriculum. The exact requirement is defined in the Specialty Specific Guidance, so confirm it there.

What evidence does a rheumatology Portfolio Pathway application need?

Evidence mapped to the 2022 curriculum capabilities: clinical case mix across inflammatory arthritis, connective tissue disease and metabolic bone disease, joint and soft tissue injection competence, biologics and DMARD governance, workplace-based assessments, multi-source feedback, audit and quality improvement, teaching and CPD, and structured reports. For a dual application you also need internal medicine evidence including the acute take. Everything should be recent, mapped to the relevant capability, and clearly organised.

Can I apply if I trained in rheumatology overseas?

Yes, but direct applications from overseas are challenging because the evidence must mirror UK rheumatology practice, including biologics and DMARD shared-care governance and, for a dual application, the GIM acute take. You need a relevant specialist qualification or at least six months of continuous specialist training in rheumatology. For many internationally trained rheumatologists the realistic route is a UK post first, building the procedural, governance and acute take evidence from inside the system.

How long does the rheumatology Portfolio Pathway take?

Most candidates take two to four years from starting evidence collection to Specialist Register entry. Rheumatology is a more cognitive specialty than the heavily procedural ones, but the breadth of inflammatory, autoimmune and metabolic bone disease, plus the dual GIM evidence, still takes time to assemble. Once submitted, the GMC takes six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months of process time on top of the evidence-building years.